Lilly criticizes Belgium's refusal to reimburse obesity drug Mounjaro

Eli Lilly publicly criticizes Belgium's decision not to reimburse its obesity treatment Mounjaro, noting no obesity medication is covered in the country. The company cites Sciensano data showing one in five adults affected and nearly 10,000 annual deaths linked to obesity-related complications. The decision reflects fiscal constraints but may impact patient access and Lilly's market penetration in Europe.